{"protocolSection":{"identificationModule":{"nctId":"NCT06593587","orgStudyIdInfo":{"id":"C3671053"},"secondaryIdInfos":[{"id":"NCT06593587","type":"REGISTRY","domain":"ClinicalTrials.gov"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea","officialTitle":"A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN OLDER ADULTS IN KOREA"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-10-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-02-03","type":"ACTUAL"},"completionDateStruct":{"date":"2025-02-03","type":"ACTUAL"},"studyFirstSubmitDate":"2024-09-09","studyFirstSubmitQcDate":"2024-09-09","studyFirstPostDateStruct":{"date":"2024-09-19","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-01-21","resultsFirstSubmitQcDate":"2026-01-21","resultsFirstPostDateStruct":{"date":"2026-02-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-21","lastUpdatePostDateStruct":{"date":"2026-02-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The goal of this clinical trial is to quantify the immune response in older Korean adults after a RSVpreF vaccination. It will also learn about the safety and tolerability of RSVpreF vaccination. The main questions it aims to answer are:\n\nWhat local reactions and systemic events do participants have after a RSVpreF vaccination? What medical problems do participants have after a RSVpreF vaccination? Researchers will compare RSVpreF to a placebo (a look-alike substance that contains no RSVpreF) to see if RSVpreF is safe and well tolerated. It will also examine the change in antibody levels (immune responses) before and after vaccination.\n\nParticipants will:\n\nReceive the RSVpreF vaccination or a placebo injection once at Visit 1. Visit the clinic a month later for a checkup and tests. Receive a phone call 1 week after vaccination, and 2 months after vaccination, for health checks.\n\nKeep a diary of their symptoms for 7 days after vaccination.","detailedDescription":"This is a Phase 3, randomized, double-blinded, placebo-controlled, multicenter trial to describe the safety, tolerability, and immunogenicity of bivalent RSVpreF in adults 60 years of age and older in Korea.\n\nThe study duration is approximately 2 months. 4 study visits are required and are comprised of 2 scheduled clinic visits and 2 scheduled telephone calls.\n\nApproximately 360 study-eligible participants will be randomized to receive either the 120-µg dose of RSVpreF or placebo in a 2:1 ratio.\n\nAfter screening and confirmation of eligibility, a prevaccination blood sample will be collected for immunogenicity assessments and a single dose of study intervention (RSVpreF or placebo) will be administered.\n\nParticipants will report daily reactogenicity data using an electronic device for 7-days or until resolution.\n\nParticipants will return approximately 1 month later for a follow-up blood draw for immunogenicity assessments and collection of safety information.\n\nA telephone follow-up visit will be conducted approximately 1 week after vaccination to review reactogenicity and approximately 2 months after vaccination to collect safety information.\n\nFor all participants, adverse events (AEs) will be collected from informed consent through 1 month following study intervention administration. Serious adverse events (SAEs) newly diagnosed chronic medical conditions (NDCMCs), and adverse events of special interest (AESIs) will be collected from informed consent throughout study participation."},"conditionsModule":{"conditions":["Respiratory Syncytial Virus"],"keywords":["Respiratory tract infection","RSV","Respiratory Syncytial Virus","Vaccine","Older adults"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Parallel","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"This study is double-blinded.\n\nThe participant, study coordinator, and all site staff will be blinded.\n\nThe majority of sponsor staff will be blinded to study intervention allocation. All laboratory testing personnel performing serological assays or diagnostic assays will remain blinded to the study intervention assigned/received throughout the study","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":378,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"RSVpreF","type":"EXPERIMENTAL","interventionNames":["Biological: RSVpreF Vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"RSVpreF Vaccine","description":"RSV Vaccine 120 mcg","armGroupLabels":["RSVpreF"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Local Reactions Within 7 Days After Vaccination","description":"Local reactions included redness, swelling and pain at injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as mild: \\> 2.0 cm to 5.0 cm, moderate: \\> 5.0 cm to 10.0 cm, severe: \\>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity, severe: prevented daily activity. Any local reaction: any redness, any swelling, or pain at the injection site of at least mild severity. Exact 2-sided 95% confidence interval (CI) was based on the Clopper and Pearson method.","timeFrame":"From Day 1 to Day 7 after vaccination"},{"measure":"Percentage of Participants With Systemic Events Within 7 Days After Vaccination","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C, severe: \\>38.9 to 40.0 deg C, and Grade 4: \\>40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From Day 1 to Day 7 after vaccination"},{"measure":"Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination","description":"An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From vaccination on Day 1 up to 1 month after vaccination"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination Throughout the Study","description":"An SAE was defined as an AE that, at any dose met one of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic; other significant medical events as judged by investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From vaccination on Day 1 up to 2 months after vaccination"},{"measure":"Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study","description":"A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"From vaccination on Day 1 up to 2 months after vaccination"},{"measure":"Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B Before Vaccination","description":"GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ for analysis.","timeFrame":"Before Vaccination"},{"measure":"Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination","description":"GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ for analysis.","timeFrame":"1 month after vaccination"},{"measure":"Geometric Mean Fold Rise (GMFR) of Neutralizing Titers (NTs) for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination","description":"Fold rises was defined as ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","timeFrame":"From before vaccination to 1 month after vaccination"}],"secondaryOutcomes":[{"measure":"Seroresponse Rates of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination","description":"Seroresponse rate was defined as the percentage of participants with a postvaccination NT \\>=4 times the LLOQ if the baseline titer (before vaccination) was below the LLOQ; or a \\>=4-fold rise from baseline if the baseline titer was\\>=LLOQ. 95% CI was based on Clopper-Pearson method.","timeFrame":"1 month after vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participants 60 years of age or older at Visit 1\n\n   * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration\n   * Female participants must not be of childbearing potential\n2. Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.\n\n   Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.\n3. Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, frequent symptom assessment by mobile device application (e-diary), and other study procedures.\n4. Participants who are ambulatory and live in the community, or in assisted-living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living (ADL).\n5. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and the protocol.\n\nExclusion Criteria:\n\n1. A confirmed diagnosis of RSV infection ≤180 days before study intervention administration.\n2. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular (IM) injection.\n3. Prior history of any subtype of Guillain-Barré syndrome (GBS) of any etiology.\n4. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.\n5. Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.\n6. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n7. Any medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n8. Individuals who receive chronic systemic treatment with immunosuppressive therapy (other than systemic corticosteroids meeting the criteria noted below), including cytotoxic agents, immunosuppressive monoclonal antibodies, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study.\n\n   * Receipt of systemic corticosteroids (≥20 mg/day of prednisone or equivalent) for\n\n     ≥14 days from 28 days before study intervention.\n   * Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.\n9. Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.\n10. Previous vaccination with any licensed or investigational RSV vaccine, or planned receipt throughout the study.\n11. Previous administration with an investigational product (drug or vaccine) within 6 months prior to study intervention administration. Participation in other studies involving an investigational product (drug or vaccine) at any time during participation in this study.\n12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.\n\n    \\-","healthyVolunteers":true,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Inha University Hospital","city":"Incheon","state":"Incheon-gwangyeoksi [incheon]","zip":"22332","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Jeonbuk National University Hospital","city":"Jeonju","state":"Jeonrabugdo","zip":"54907","country":"South Korea","geoPoint":{"lat":35.82483,"lon":127.14796}},{"facility":"Chonnam National University Hospital","city":"Gwangju","state":"Kwangju-kwangyǒkshi","zip":"61469","country":"South Korea","geoPoint":{"lat":35.15472,"lon":126.91556}},{"facility":"Korea University Ansan Hospital","city":"Ansan-si","state":"Kyǒnggi-do","zip":"15355","country":"South Korea","geoPoint":{"lat":37.32361,"lon":126.82194}},{"facility":"Soon Chun Hyang University Bucheon Hospital","city":"Bucheon-si","state":"Kyǒnggi-do","zip":"14584","country":"South Korea","geoPoint":{"lat":37.49889,"lon":126.78306}},{"facility":"The Catholic University Of Korea St. Vincent's Hospital","city":"Suwon","state":"Kyǒnggi-do","zip":"16247","country":"South Korea","geoPoint":{"lat":37.27818,"lon":127.03164}},{"facility":"Ajou University Hospital","city":"Suwon","state":"Kyǒnggi-do","zip":"16499","country":"South Korea","geoPoint":{"lat":37.27818,"lon":127.03164}},{"facility":"Dong-A University Hospital","city":"Busan","state":"Pusan-kwangyǒkshi","zip":"49201","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Severance Hospital, Yonsei University Health System","city":"Seoul","state":"Seoul-teukbyeolsi [seoul]","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hallym University Kangdong Sacred Heart Hospital","city":"Seoul","state":"Seoul-teukbyeolsi [seoul]","zip":"05355","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","state":"Seoul-teukbyeolsi [seoul]","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"The Catholic Univ. of Korea Seoul St. Mary's Hospital","city":"Seoul","state":"Seoul-teukbyeolsi [seoul]","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hallym University Kangnam Sacred Heart Hospital","city":"Seoul","state":"Seoul-teukbyeolsi [seoul]","zip":"07441","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ewha Womans University Mokdong Hospital","city":"Seoul","state":"Seoul-teukbyeolsi [seoul]","zip":"07985","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University Guro Hospital","city":"Seoul","state":"Seoul-teukbyeolsi [seoul]","zip":"08308","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Kyungpook National University Hospital","city":"Daegu","state":"Taegu-kwangyǒkshi","zip":"41944","country":"South Korea","geoPoint":{"lat":35.87102,"lon":128.60121}}]},"referencesModule":{"references":[{"pmid":"42797593","type":"DERIVED","citation":"Choi WS, Quan K, Baber JA, Jaques A, van Rensburg KJ, Li W, Cutler MW, Kalinina EV, Anderson AS, Swanson KA, Gurtman A, Munjal I; Jeongwol C3671053 Clinical Trial Group. A Randomized Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Bivalent RSVpreF Vaccine in Older Adults in Korea. Vaccines (Basel). 2026 Sep 3;14(9):773. doi: 10.3390/vaccines14090773."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C3671053"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 384 participants were screened, out of which 6 were screen failures and 378 participants were randomized 2:1 to receive respiratory syncytial virus stabilized prefusion F subunit vaccine (RSVpreF) or placebo.","recruitmentDetails":"This study was conducted at 16 sites in the Republic of Korea.","groups":[{"id":"FG000","title":"RSVpreF 120 mcg","description":"Participants were randomized to receive a single dose of RSVpreF 120 microgram (mcg) intramuscularly on Day 1."},{"id":"FG001","title":"Placebo","description":"Participants were randomized to receive a single dose of placebo intramuscularly on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"252"},{"groupId":"FG001","numSubjects":"126"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"251"},{"groupId":"FG001","numSubjects":"126"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"250"},{"groupId":"FG001","numSubjects":"126"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Randomized, not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all screened participants who received the study intervention in the study.","groups":[{"id":"BG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"BG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"251"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"377"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67.3","spread":"5.18"},{"groupId":"BG001","value":"67.3","spread":"5.19"},{"groupId":"BG002","value":"67.3","spread":"5.17"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"244"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"133"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Race","categories":[{"title":"Asian","measurements":[{"groupId":"BG000","value":"251"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"377"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Ethnicity","categories":[{"title":"Non-Hispanic/non-Latino","measurements":[{"groupId":"BG000","value":"251"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"377"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions Within 7 Days After Vaccination","description":"Local reactions included redness, swelling and pain at injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as mild: \\> 2.0 cm to 5.0 cm, moderate: \\> 5.0 cm to 10.0 cm, severe: \\>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity, severe: prevented daily activity. Any local reaction: any redness, any swelling, or pain at the injection site of at least mild severity. Exact 2-sided 95% confidence interval (CI) was based on the Clopper and Pearson method.","populationDescription":"Safety population included all screened participants who received the study intervention in the study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 to Day 7 after vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"Pain at injection site: any","categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"8.5","upperLimit":"17.1"},{"groupId":"OG001","value":"3.2","lowerLimit":"0.9","upperLimit":"7.9"}]}]},{"title":"Pain at injection site: mild","categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"7.9","upperLimit":"16.2"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.5","upperLimit":"6.8"}]}]},{"title":"Pain at injection site: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.1","upperLimit":"2.8"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]},{"title":"Pain at injection site: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Redness: any","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"1.1","upperLimit":"5.7"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]},{"title":"Redness: mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.4","upperLimit":"4.0"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]},{"title":"Redness: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.1","upperLimit":"2.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Redness: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Swelling: any","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.4","upperLimit":"4.0"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]},{"title":"Swelling: mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.2","upperLimit":"3.5"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]},{"title":"Swelling: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Swelling: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Any local reaction: any","categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"10.6","upperLimit":"19.7"},{"groupId":"OG001","value":"3.2","lowerLimit":"0.9","upperLimit":"7.9"}]}]},{"title":"Any local reaction: mild","categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"8.5","upperLimit":"17.1"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.5","upperLimit":"6.8"}]}]},{"title":"Any local reaction: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"0.6","upperLimit":"4.6"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]},{"title":"Any local reaction: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events Within 7 Days After Vaccination","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C, severe: \\>38.9 to 40.0 deg C, and Grade 4: \\>40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all screened participants who received the study intervention in the study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 to Day 7 after vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"Fever: >=38.0°C","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.2","upperLimit":"5.6"}]}]},{"title":"Fever: >=38.0°C to 38.4°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.2","upperLimit":"5.6"}]}]},{"title":"Fever: >38.4°C to 38.9°C","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Fever: >38.9°C to 40.0°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Fever: >40.0°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Fatigue: any","categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"18.0","upperLimit":"28.8"},{"groupId":"OG001","value":"26.2","lowerLimit":"18.8","upperLimit":"34.8"}]}]},{"title":"Fatigue: mild","categories":[{"measurements":[{"groupId":"OG000","value":"17.9","lowerLimit":"13.4","upperLimit":"23.2"},{"groupId":"OG001","value":"15.9","lowerLimit":"10.0","upperLimit":"23.4"}]}]},{"title":"Fatigue: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"2.8","upperLimit":"8.7"},{"groupId":"OG001","value":"10.3","lowerLimit":"5.6","upperLimit":"17.0"}]}]},{"title":"Fatigue: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Headache: any","categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"8.9","upperLimit":"17.5"},{"groupId":"OG001","value":"11.1","lowerLimit":"6.2","upperLimit":"17.9"}]}]},{"title":"Headache: mild","categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"7.9","upperLimit":"16.2"},{"groupId":"OG001","value":"8.7","lowerLimit":"4.4","upperLimit":"15.1"}]}]},{"title":"Headache: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.2","upperLimit":"3.5"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.5","upperLimit":"6.8"}]}]},{"title":"Headache: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Muscle pain: any","categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"11.3","upperLimit":"20.6"},{"groupId":"OG001","value":"9.5","lowerLimit":"5.0","upperLimit":"16.0"}]}]},{"title":"Muscle pain: mild","categories":[{"measurements":[{"groupId":"OG000","value":"12.0","lowerLimit":"8.2","upperLimit":"16.6"},{"groupId":"OG001","value":"5.6","lowerLimit":"2.3","upperLimit":"11.1"}]}]},{"title":"Muscle pain: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"1.7","upperLimit":"6.7"},{"groupId":"OG001","value":"4.0","lowerLimit":"1.3","upperLimit":"9.0"}]}]},{"title":"Muscle pain: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Joint pain: any","categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"5.9","upperLimit":"13.4"},{"groupId":"OG001","value":"7.9","lowerLimit":"3.9","upperLimit":"14.1"}]}]},{"title":"Joint pain: mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.0","lowerLimit":"3.4","upperLimit":"9.7"},{"groupId":"OG001","value":"4.0","lowerLimit":"1.3","upperLimit":"9.0"}]}]},{"title":"Joint pain: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.4","upperLimit":"6.2"},{"groupId":"OG001","value":"4.0","lowerLimit":"1.3","upperLimit":"9.0"}]}]},{"title":"Joint pain: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Nausea: any","categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"1.7","upperLimit":"6.7"},{"groupId":"OG001","value":"6.3","lowerLimit":"2.8","upperLimit":"12.1"}]}]},{"title":"Nausea: mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"1.7","upperLimit":"6.7"},{"groupId":"OG001","value":"4.0","lowerLimit":"1.3","upperLimit":"9.0"}]}]},{"title":"Nausea: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"15"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.5","upperLimit":"6.8"}]}]},{"title":"Nausea: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Vomiting: any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]},{"title":"Vomiting: mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]},{"title":"Vomiting: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Vomiting: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Diarrhea: any","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"2.5","upperLimit":"8.2"},{"groupId":"OG001","value":"4.0","lowerLimit":"1.3","upperLimit":"9.0"}]}]},{"title":"Diarrhea: mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"2.5","upperLimit":"8.2"},{"groupId":"OG001","value":"4.0","lowerLimit":"1.3","upperLimit":"9.0"}]}]},{"title":"Diarrhea: moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]},{"title":"Diarrhea: severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"1.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination","description":"An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all screened participants who received the study intervention in the study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination on Day 1 up to 1 month after vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"1.7","upperLimit":"6.7"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination Throughout the Study","description":"An SAE was defined as an AE that, at any dose met one of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic; other significant medical events as judged by investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all screened participants who received the study intervention in the study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination on Day 1 up to 2 months after vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.1","upperLimit":"2.8"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study","description":"A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all screened participants who received the study intervention in the study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination on Day 1 up to 2 months after vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.2","upperLimit":"3.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.9"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B Before Vaccination","description":"GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ for analysis.","populationDescription":"Evaluable immunogenicity population: all participants who were eligible and received the study intervention to which they were randomized, had 1-month postvaccination blood collection visit within 27 to 42 days after vaccination, had at least 1 valid and determinate assay result 1 month after vaccination and had no major protocol violations from vaccination through the 1-month postvaccination blood draw. Here \"Number Analyzed\" refers to number of participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Before Vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"RSV A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1472","lowerLimit":"1326","upperLimit":"1636"},{"groupId":"OG001","value":"1617","lowerLimit":"1402","upperLimit":"1866"}]}]},{"title":"RSV B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1957","lowerLimit":"1766","upperLimit":"2168"},{"groupId":"OG001","value":"1865","lowerLimit":"1601","upperLimit":"2174"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination","description":"GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ for analysis.","populationDescription":"Evaluable immunogenicity population: all participants who were eligible and received the study intervention to which they were randomized, had 1-month postvaccination blood collection visit within 27 to 42 days after vaccination, had at least 1 valid and determinate assay result 1 month after vaccination and had no major protocol violations from vaccination through the 1-month postvaccination blood draw. Here \"Number Analyzed\" refers to number of participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"RSV A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"125"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14240","lowerLimit":"12977","upperLimit":"15625"},{"groupId":"OG001","value":"1397","lowerLimit":"1199","upperLimit":"1628"}]}]},{"title":"RSV B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16277","lowerLimit":"14623","upperLimit":"18117"},{"groupId":"OG001","value":"1813","lowerLimit":"1554","upperLimit":"2115"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Rise (GMFR) of Neutralizing Titers (NTs) for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination","description":"Fold rises was defined as ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","populationDescription":"Evaluable immunogenicity population: all participants who were eligible and received the study intervention to which they were randomized, had 1-month postvaccination blood collection visit within 27 to 42 days after vaccination, had at least 1 valid and determinate assay result 1 month after vaccination and had no major protocol violations from vaccination through the 1-month postvaccination blood draw. Here \"Number Analyzed\" refers to number of participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"From before vaccination to 1 month after vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"RSV A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"125"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"8.51","upperLimit":"10.67"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.78","upperLimit":"0.94"}]}]},{"title":"RSV B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"7.37","upperLimit":"9.39"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.89","upperLimit":"1.06"}]}]}]},{"type":"SECONDARY","title":"Seroresponse Rates of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination","description":"Seroresponse rate was defined as the percentage of participants with a postvaccination NT \\>=4 times the LLOQ if the baseline titer (before vaccination) was below the LLOQ; or a \\>=4-fold rise from baseline if the baseline titer was\\>=LLOQ. 95% CI was based on Clopper-Pearson method.","populationDescription":"Evaluable immunogenicity population: all participants who were eligible and received the study intervention to which they were randomized, had 1-month postvaccination blood collection visit within 27 to 42 days after vaccination, had at least 1 valid and determinate assay result 1 month after vaccination and had no major protocol violations from vaccination through the 1-month postvaccination blood draw. Here \"Number Analyzed\" refers to number of participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"1 month after vaccination","groups":[{"id":"OG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection."},{"id":"OG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"RSV A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"125"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","lowerLimit":"75.6","upperLimit":"85.7"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.4"}]}]},{"title":"RSV B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.9","lowerLimit":"70.1","upperLimit":"81.1"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.0","upperLimit":"4.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"All-cause mortality and SAEs: From vaccination on Day 1 up to 2 months after vaccination. Other AEs (non-systematic assessment): From vaccination on Day 1 up to 1 month after vaccination; Local reactions and systemic events (systematic assessment): From Day 1 to Day 7 after vaccination","description":"Same event may appear as both non-SAE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Safety population included all screened participants who received the study intervention in the study.","eventGroups":[{"id":"EG000","title":"RSVpreF 120 mcg","description":"Participants were administered a single dose of RSVpreF 120 mcg on Day 1 via IM injection.","deathsNumAffected":0,"deathsNumAtRisk":251,"seriousNumAffected":2,"seriousNumAtRisk":251,"otherNumAffected":100,"otherNumAtRisk":251},{"id":"EG001","title":"Placebo","description":"Participants were administered a single dose of placebo on Day 1 via IM injection.","deathsNumAffected":0,"deathsNumAtRisk":126,"seriousNumAffected":1,"seriousNumAtRisk":126,"otherNumAffected":43,"otherNumAtRisk":126}],"seriousEvents":[{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":251},{"groupId":"EG001","numAffected":1,"numAtRisk":126}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]}],"otherEvents":[{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Varicella zoster virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":251},{"groupId":"EG001","numAffected":1,"numAtRisk":126}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":0,"numAtRisk":126}]},{"term":"Fatigue (FATIGUE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":58,"numAtRisk":251},{"groupId":"EG001","numAffected":33,"numAtRisk":126}]},{"term":"Injection site pain (PAIN AT INJECTION SITE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":251},{"groupId":"EG001","numAffected":4,"numAtRisk":126}]},{"term":"Pyrexia (FEVER)","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":251},{"groupId":"EG001","numAffected":2,"numAtRisk":126}]},{"term":"Swelling (SWELLING)","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":251},{"groupId":"EG001","numAffected":1,"numAtRisk":126}]},{"term":"Diarrhoea (DIARRHEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":251},{"groupId":"EG001","numAffected":5,"numAtRisk":126}]},{"term":"Nausea (NAUSEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":251},{"groupId":"EG001","numAffected":8,"numAtRisk":126}]},{"term":"Vomiting (VOMITING)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":251},{"groupId":"EG001","numAffected":1,"numAtRisk":126}]},{"term":"Arthralgia (JOINT PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":251},{"groupId":"EG001","numAffected":10,"numAtRisk":126}]},{"term":"Myalgia (MUSCLE PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":251},{"groupId":"EG001","numAffected":12,"numAtRisk":126}]},{"term":"Headache (HEADACHE)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":251},{"groupId":"EG001","numAffected":14,"numAtRisk":126}]},{"term":"Erythema (REDNESS)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":251},{"groupId":"EG001","numAffected":1,"numAtRisk":126}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2025-03-17","uploadDate":"2026-01-09T10:41","filename":"Prot_000.pdf","size":845595},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-08-12","uploadDate":"2026-01-09T10:42","filename":"SAP_001.pdf","size":2478601}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D012141","term":"Respiratory Tract Infections"}],"ancestors":[{"id":"D007239","term":"Infections"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}